Recent advances in personalized medicine are turning the idea of customized treatment into a reality. Personalized medicine generally refers to medical diagnosis and treatment based on an individual’s genetic and physiological makeup. At the forefront of the technology are genetic- and biomarker-based diagnostic assays.
For example, an individual’s genes, proteins and metabolites can be used as indicators or “biomarkers” of that individual’s state of health, including susceptibility to disease. The presence or amount of a particular biomarker in a biological sample can reveal that an individual is predisposed to a particular disease or will respond favorably to a particular treatment. Armed with this information, health care providers can diagnose and select the safest and most efficacious treatment at the outset, which can maximize the individual’s chances of successful treatment, reduce side effects and also reduce costs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
